Abstract Number: 1678 • ACR Convergence 2021
Favorable Balance of Benefit and Harm of Long-Term, Low Dose Prednisolone Added to Standard Treatment in Rheumatoid Arthritis Patients Aged 65+: The Pragmatic, Multicenter, Placebo-Controlled GLORIA Trial
Background/Purpose: Low-dose glucocorticoid (GC) therapy is widely used in rheumatoid arthritis (RA) but the balance of benefit and harm is still unclear. We studied the…Abstract Number: 1735 • ACR Convergence 2021
Glucocorticoid Discontinuation in Patients with Systemic Lupus Erythematosus with Prior Severe Organ Manifestation
Background/Purpose: Most long-term damage in systemic lupus erythematosus (SLE) has been attributed to continuous glucocorticoid use; however, glucocorticoid discontinuation is occasionally associated with disease flare-ups.…Abstract Number: 1914 • ACR Convergence 2021
Immunomodulatory and Immunosuppressive Medication Modification Among Rheumatology Patients at the Time of COVID-19 Vaccination
Background/Purpose: Due to concerns about underlying immune dysregulation and immunosuppression, patients with systemic rheumatic diseases (SRD) may have modified their medications at the time of…Abstract Number: 0058 • ACR Convergence 2021
Effect of Anti-inflammatory Drugs on Intestinal Epithelial Damage and Bacterial Translocation in the Adjuvant-induced Arthritis Model
Background/Purpose: The intestine is no longer considered as an organ targeted by spondyloarthritis (SpA) but also an actor of the disease alongside environmental and immunological…Abstract Number: 0153 • ACR Convergence 2021
Echogenic and Hypervascular Synovium Detected on Ultrasound Are Predictive of a Favorable Response After Intra-articular Corticosteroid Injection in Patients with Knee Osteoarthritis
Background/Purpose: Intra-articular corticosteroids (IACS) are commonly used for symptom management in knee osteoarthritis (KOA) patients, despite the fact that many patients do not respond to…Abstract Number: 0492 • ACR Convergence 2021
Racial Differences in Glucocorticoid Use Among Medicaid Beneficiaries with Incident Systemic Lupus Erythematosus
Background/Purpose: Glucocorticoids (GCs) are an integral part of systemic lupus erythematosus (SLE) treatment. Long-term use of GCs is associated with adverse effects. This study evaluated…Abstract Number: 0730 • ACR Convergence 2021
Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
Background/Purpose: Knee osteoarthritis (OA) is a painful condition leading to joint damage and impaired function. Intra-articular (IA) corticosteroid injections are frequently prescribed to treat pain.…Abstract Number: 1116 • ACR Convergence 2021
Disease Characteristics of Steroid-Induced Spinal Epidural Lipomatosis: A Systematic Review
Background/Purpose: Steroid-induced epidural lipomatosis (SEL) is a rare phenomenon causing neuronal compression from adipose tissue deposition in the epidural space. We analyzed the available literature…Abstract Number: 1242 • ACR Convergence 2021
Sex Differences in Treatment Response to Three Different Biological Treatments and Corticosteroids in Patients with Early Rheumatoid Arthritis
Background/Purpose: To investigate sex differences in clinical response to three different biological treatments in combination with methotrexate (MTX) versus MTX plus corticosteroids (active conventional treatment;…Abstract Number: 1264 • ACR Convergence 2021
Racial Differences in Chronic Glucocorticoid Use in Patients with SLE: A Cross Sectional Study
Background/Purpose: Black patients with systemic lupus erythematosus (SLE) face higher rates of morbidity and mortality compared to White patients. Long-term glucocorticoid use has been associated…Abstract Number: 1408 • ACR Convergence 2021
Treatment of Giant Cell Arteritis in the ARTESER Multicenter Study of 1675 Patients
Background/Purpose: Glucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment,…Abstract Number: 1571 • ACR Convergence 2020
Distinct T Cell Responses in Inflammatory Arthritis Associated with Combined CTLA-4 and PD-1 Inhibitor Therapy
Background/Purpose: Despite of unprecedented clinical success in cancer therapeutics, immune checkpoint inhibitors (ICIs) are associated with immune-related adverse events (irAEs), including arthritis (arthritis-irAE). Arthritis-irAE can…Abstract Number: 1625 • ACR Convergence 2020
Pneumocystis Jiroveci Pneumonia in Immunocompromised Patients with Rheumatologic Disease in a Single, Tertiary Medical Center
Background/Purpose: Pneumocystis jiroveci pneumonia (PJP) is rare, but can be fatal among immunocompromised. There is no consensus on indications for PJP prophylaxis in rheumatologic patients.…Abstract Number: 1650 • ACR Convergence 2020
A Double-Blind Randomized Trial to Evaluate the Efficacy of Corticosteroid Injections for Osteoarthritis of the Knee Using Mobile Devices
Background/Purpose: The value of intra-articular (IA) corticosteroid injections for osteoarthritis of the knee (KOA) has recently been called into question. Variability in clinical trial design…Abstract Number: 1651 • ACR Convergence 2020
Efficacy and Safety of Multiple Intra-articular Corticosteroid Injections for Osteoarthritis – a Systematic Review and Meta-analysis of Randomised Controlled Trials and Observational Studies
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis worldwide and is becoming more prevalent with the increasing age of the population. As Intra-articular…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 14
- Next Page »
